Literature DB >> 16142762

Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis.

Paco M J Welsing1, Jaap Fransen, Piet L C M van Riel.   

Abstract

OBJECTIVE: Based on comparisons of short-term cohort studies or cross-sectional samples of patients from different calendar times, it has been suggested that present patients with rheumatoid arthritis (RA) have a milder disease course compared with that of patients in past decades. This study was undertaken to investigate whether the course of disease activity and functional disability in patients with RA has become milder over the past several years.
METHODS: We used the Nijmegen inception cohort of early RA, which included all patients with newly diagnosed RA who had attended the department of rheumatology at Radboud University Nijmegen Medical Centre since 1985. Patients were assessed for disease activity by the Disease Activity Score in 28 joints (DAS28) every 3 months and for functional disability by the Health Assessment Questionnaire (HAQ) disability index (DI) every 6 months. Within the total cohort, 4 subcohorts were defined, based on the date of inclusion of the patients (1985-1990, 1990-1995, 1995-2000, 2000-2005). To investigate whether the course of disease activity and functional disability (over time) was different between the subcohorts, longitudinal regression analysis (linear mixed models) was used, with the DAS28 and HAQ DI over time as outcome variables, respectively, and subcohort as the independent variable, correcting for baseline demographic and clinical characteristics. The treatment strategy was compared between the subcohorts.
RESULTS: The DAS28 at baseline and over the first 5 years of disease was lower in the more recent subcohorts. The HAQ DI did not show improvement but instead a trend toward worsening functional disability. Using longitudinal regression it was shown that disease activity improved early in the disease course and stabilized thereafter, and that this improvement was greater in patients in the more recent subcohorts and in patients with a higher baseline DAS28. Initially, the HAQ DI also improved but stabilized thereafter, and this initial improvement was less pronounced in patients in the more recent subcohorts and was greater for patients with a higher baseline HAQ DI. The treatment strategy was more aggressive in the more recent subcohorts, as shown by a shorter duration from diagnosis to the start of treatment with prednisone or disease-modifying antirheumatic drugs (DMARDs), and a greater prevalence of DMARD therapy.
CONCLUSION: The course of disease activity in RA patients has become milder in more recent years. The reason for this improving trend remains to be elucidated, although the trend coincides with a more aggressive treatment strategy.

Entities:  

Mesh:

Year:  2005        PMID: 16142762     DOI: 10.1002/art.21259

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  28 in total

1.  Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis.

Authors:  Ayako Nakajima; Eisuke Inoue; Yoko Shimizu; Akiko Kobayashi; Kumi Shidara; Naoki Sugimoto; Yohei Seto; Eiichi Tanaka; Atsuo Taniguchi; Shigeki Momohara; Hisashi Yamanaka
Journal:  Clin Rheumatol       Date:  2014-07-31       Impact factor: 2.980

2.  Major trends in the manifestations and treatment of rheumatoid arthritis in a multiethnic cohort in Singapore.

Authors:  Ee Tzun Koh; Justina Wei Lynn Tan; Bernard Yu-Hor Thong; Cheng Lay Teh; Tsui Yee Lian; Weng Giap Law; Arul Earnest; Kok Ooi Kong; Tang Ching Lau; Yew Kuang Cheng; Hwee Siew Howe; Wern Hui Yong; Faith Li-Ann Chia; Hiok Hee Chng; Khai Pang Leong
Journal:  Rheumatol Int       Date:  2012-12-28       Impact factor: 2.631

Review 3.  Changing incidence of orthopedic surgery in rheumatic disease: contributing factors.

Authors:  Elana J Bernstein; Lisa A Mandl
Journal:  Curr Rheumatol Rep       Date:  2013-10       Impact factor: 4.592

4.  Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US.

Authors:  Saralynn Allaire; Frederick Wolfe; Jingbo Niu; Michael P Lavalley
Journal:  Arthritis Rheum       Date:  2008-04-15

5.  Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity.

Authors:  Bert Vander Cruyssen; Patrick Durez; Rene Westhovens; Filip De Keyser
Journal:  Arthritis Res Ther       Date:  2010-05-06       Impact factor: 5.156

6.  Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritis.

Authors:  Timothy R D J Radstake; Jaap Fransen; Erik J M Toonen; Marieke J H Coenen; Agnes E Eijsbouts; Rachelle Donn; Frank H J van den Hoogen; Piet L C M van Riel
Journal:  Ann Rheum Dis       Date:  2007-04-24       Impact factor: 19.103

7.  Decline in rheumatoid vasculitis prevalence among US veterans: a retrospective cross-sectional study.

Authors:  Christie Bartels; Carolyn Bell; Ann Rosenthal; Kazuhiko Shinki; Alan Bridges
Journal:  Arthritis Rheum       Date:  2009-09

8.  Rheumatologists' knowledge, attitude and current management of fatigue in patients with rheumatoid arthritis (RA).

Authors:  Han Repping-Wuts; Piet van Riel; Theo van Achterberg
Journal:  Clin Rheumatol       Date:  2008-07-12       Impact factor: 2.980

9.  Influence of patient personality in the treatment of rheumatoid arthritis.

Authors:  Leticia Leon; Marta Redondo; Alberto Garcia-Vadillo; Miguel A Perez-Nieto; Luis Rodriguez-Rodriguez; Juan A Jover; Isidoro Gonzalez-Alvaro; Lydia Abasolo
Journal:  Rheumatol Int       Date:  2016-09-10       Impact factor: 2.631

Review 10.  Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs.

Authors:  Tuulikki Sokka; Minja Envalds; Theodore Pincus
Journal:  Mod Rheumatol       Date:  2008-04-25       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.